Medifast, Inc. (NYSE:MED) announced the resignation of Jason L. Groves, Esq., its Chief Legal Officer and Corporate Secretary, effective as of Thursday. The company, with a market capitalization of $128.5 million, disclosed in a press release statement, filed with the Securities and Exchange Commission, that Mr. Groves and Medifast entered into a separation and release agreement on Sunday.
Under the terms of the agreement, Mr. Groves will receive a one-time lump sum cash severance payment equal to one month of his annual base salary, less applicable taxes and withholdings. The payment is contingent upon Mr. Groves’ non-revocation of the separation agreement and compliance with its terms and conditions.
According to the filing, Mr. Groves’ departure was not the result of any disagreement with the company or any issue related to Medifast’s operations, policies, or practices. Medifast has started a search for a permanent replacement for the Chief Legal Officer position.The leadership transition comes as Medifast trades at $12.53, which InvestingPro analysis suggests is undervalued based on its Fair Value assessment. For deeper insights into Medifast’s financial health and executive decisions, investors can access the comprehensive Pro Research Report available exclusively on InvestingPro.
This information is based on a press release statement included in the company’s SEC filing.
In other recent news, Medifast Inc. reported its Q1 2026 earnings, showcasing an earnings per share (EPS) of -$0.19, surpassing analyst expectations of -$0.36. This represents a positive surprise of 47.22%. However, the company reported revenue of $76 million, which fell short of the anticipated $85.5 million, indicating an 11.11% miss. In another development, Medifast announced the appointment of Nicholas Johnson as the new Chief Executive Officer, effective June 1, 2026. Johnson will take over from Dan Chard, who will continue as Chairman of the Board. This leadership change follows a transition plan disclosed earlier in January. These recent developments reflect significant changes in Medifast’s financial performance and leadership structure.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Most traders can read a chart. The hard part is the moment: entry window open, pattern forming, and you're still waiting for more confirmation. That's the conviction gap — and our chart analysis closes it. Unlike other AIs that just read data, our Vision AI literally "sees" your charts and hands you a complete trading plan: entry, stop-loss, and profit target in under 60 seconds. Know exactly what to do next, every time.